Wide uptake of active surveillance across VA medical system

A research letter in the Journal of the American Medical Association reports a major uptake in the application of active surveillance as a first-line form of management of prostate cancer across the Veterans Affairs health system here in the US since 2005. … READ MORE …

Short-term ADT for men on active surveillance?

One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …

Tookad-Soluble + VTP effective and safe in treatment of low-risk prostate cancer

Another new media report (based on data just published in Lancet Oncology) states that “vascular-targeted photodynamic therapy” or VTP in combination with an experimental drug called padeliporfin or WST11 can be used to successfully treat low-risk prostate cancer. … READ MORE …

PRIAS reports data from a 5,000+ patient active surveillance study

Data from a recent paper in European Urology has further confirmed the value of active surveillance as a first-line management option for men diagnosed with low-risk prostate cancer. It has also confirm recent guidance for when men on active surveillance actually need to be advised that treatment is probably wise. … READ MORE …

Just “delaying” surgery does increase risk … but it’s not active surveillance

A key question for men diagnosed with low-risk prostate cancer is always going to be whether, and for how long, they can defer treatment without increasing the risk that delayed treatment will be less effective (or riskier) in some ways. … READ MORE …

One patient’s journey to active surveillance

A personal story on the MedPage Today web site this week tells a tale of how one 63-year-old professional journalist trod his own journey to management of his low-risk prostate cancer on active surveillance back in 2010. It may be instructive for many other patients newly diagnosed with low- and very low-risk prostate cancer.

ICER/Families USA “Proven Best Choices” for treatment of low-risk prostate cancer

According to a report from Kaiser Health News, the consumer organization Families USA is collaborating with the Institute for Clinical and Economic Review (ICER) to provide a series of “Proven Best Choices” guides for patients about screening and treatments for selected disorders. … READ MORE …